Status:
UNKNOWN
Cerebral Neuroinflammation During Major Depressive Episode
Lead Sponsor:
University Hospital, Toulouse
Collaborating Sponsors:
Institut National de la Santé Et de la Recherche Médicale, France
Conditions:
Depressive Disorder
Eligibility:
All Genders
25-55 years
Phase:
NA
Brief Summary
the investigators make the following assumptions: 1) neuroinflammation in MDD can be measured by the \[18 F \] DPA- 714 ; 2) it is accompanied by anatomical and functional changes in the frontal subco...
Detailed Description
The most widespread pathophysiological hypothesis in major depressive disorder (MDD), is the hypothesis of monoamine deficit. The most used antidepressants in everyday clinical practice act by inhibit...
Eligibility Criteria
Inclusion
- Inclusion criteria for all groups:
- Written agreement for participation
- Able to understand instructions and information data
- Inclusion criteria for the experimental group:
- Responding to MDD criteria (DSM-5)
- MADRS score\> 20
- Antidepressant medication considered ineffective and before the introduction of a new treatment according to the recommendations (unchanged dosage for at least a week and plasma levels within the therapeutic range)
- Inclusion criteria for the pathological control group :
- Having met MDD criteria (DSM-5)
- In remission for 8 weeks according to the DSM-5
- MADRS score \<10
- Treated with antidepressants (unchanged dosage for at least week)
- Inclusion criteria for the control group :
- Without any neurological or psychiatric previous disorder
- CRPus \< 5mg/L
- Exclusion criteria for all groups:
- Patients without public insurance regime.
- Specific contraindication to the use of MRI (metallic material) or PET (specific allergy related to the ligand).
- Pregnant and breastfeeding women
- Persons deprived of liberty by judicial or administrative decision
- People hospitalized without consent, or subject to legal protection
- Persons unable to consent
- Patients with a neurodegenerative disease, bipolar disease, chronic psychotic disorder, addictive disorder, Obsessive Compulsive Disorder, Post-Traumatic Stress disorder (PCL-S\> ou =45), known system pathology
- Patients with a history of stroke
- Patients with an acute infectious disease
- Patients with chronic inflammatory pathology.
- Patients treated with anti-inflammatory and/or immunosuppressive, and/or antipsychotics, and/or diazepam
- Exclusion criteria for control group:
- No significant psychiatric or somatic history.
- No psychotropic treatment
- Suicidal risk (C-SSRS)
- Anxiety Disorders (MINI)
Exclusion
Key Trial Info
Start Date :
December 7 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03314155
Start Date
December 7 2018
End Date
January 1 2024
Last Update
March 30 2023
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital de Psychiatrie
Toulouse, Midi-Pyrénées, France, 31059
2
CHU Bordeaux
Bordeaux, Nouvelle-Aquitaine, France, 33076
3
CHRU Lapeyronie
Montpellier, Occitanie, France, 34295
4
Clinique Psychiatrique Universitaire CHRU Tours
Tours, Val-De-Loire, France, 37540